<DOC>
	<DOCNO>NCT02602249</DOCNO>
	<brief_summary>In study , safety effect MUC1-gene-DC-CTL MUC1-peptide-DC-CTL human gastric cancer go investigate .</brief_summary>
	<brief_title>Clinical Safety Preliminary Efficacy MUC1-DC-CTL Treatment Stage IV Gastric Cancer .</brief_title>
	<detailed_description>PBMC patient separate peripheral blood.DCs infect MUC1 pulse MUC-1 peptide make respectively PBMC , respectively culture T cell MUC1-gene-DC-CTL MUC1-peptide-DC-CTL infuse patient immunotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Sex : male female Age : 18 80 year Histology : gastric cancer Clinical stage : stage IV Karnofsky performance status : 50 % Expected survival : 2 month Laboratory test result 7 day start treatment : White blood cell : 3.0 × 109/L Platelets : 100 × 109/L Neutrophils : 1.5 × 109/L Hemoglobin : 80g/L Serum glutamate pyruvate transaminase : le 2.5 fold upper normal limit ( ULN ) Serum glutamicoxal ( ) acetic transaminase : le 2.5 × ULN Serum bilirubin : le 1.25 × ULN Serum creatinine : le 1.25 × ULN Pregnancy test : test woman childbearing period must negative 7 day start treatment Contraception : male female subject childbearing period must adopt reliable method contraception entry study 30 day stop study Informed consent : subject must ability understand voluntarily sign write informed consent History neoplasm : neoplasms Medical history : mental disease , congestive heart failure , severe coronary artery disease , cardiac arrhythmia , concomitant corticosteroid therapy Metastasis : clinical symptom brain metastasis Other clinical trial : subject receive clinical trial study Laboratory test : serum test human immunodeficiency virus , hepatitis B virus , hepatitis C virus positive Woman : pregnant lactate woman Compliance : poor compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>